Wednesday, December 30, 2020 - Even though a generic version of Truvada is on the market, its price is only about 10% cheaper than the original. Truvada sold the rights to Teva Pharmaceuticals, an Israeli company, to sell generic Truvada before the patent expires in September of 2021. Truvada cost about $1800 per month while Teva's generic brand cost about $1500, not much saving. Next year, however, the price of generic Truvada drugs should plummet and compete with other countries that offer the drug for pennies on the dollar. According to POV.com, "The Food and Drug Administration approved Truvada for HIV treatment in 2004 and PrEP in 2012. Although tenofovir disoproxil fumarate (TDF) is already off-patent, the patent for emtricitabine is not set to expire until September 2021." POV tells readers that the price of generic Truvada alternatives will not drop until after many other companies enter the market in September.
Gilead Sciences, the maker of Truvada, hopes to transition Truvada users to Descovy the company's other HIV treatment and prophylactic transmission preventative drug. Researchers welcome the switch because Descovy appears to come with much milder side effects which call into question why Descovy was not offered in the past. Lawsuits have been filed that accuse Gilead of deliberately keeping their safer drug from the market to maximize the company's profits while disregarding patient safety. Contact a Truvada attorneys to recover compensation for damages you have suffered as a result of this dangerous drug and get a free consultation and no obligation to file a claim.
Gilead went to the extraordinary measure of partnering with the FDA in Washington to offer Truvada for free to HIV negative individuals that wanted to use the drug for prophylactic purposes. Gilead's critics accuse the company of attempting to extend their Truvada monopoly and not to help the public as the free drug program addresses only about 10% of the people that need Truvada and cannot afford it. Gilead is making 2 million bottles of Truvada available for free and has now started to replace Truvada with Descovy. Truvada carries the risk of osteoporosis and kidney failure. Truvada's detrimental side effects have been reported by those who have filed lawsuits against Gilead for failing to warn them of Truvada's dangers. Now that a generic drug is on the market, United Health Care, the nation's largest health insurance company, has decided not to cover the cost of Descovy.
Truvada, Descovy, and their generic competition may be put out of business soon as people start to take the antiretroviral drug via monthly injection rather than have to remember to take Truvada every single day. For those living with the virus, Truvada needs to be taken daily to build up in the blood. When a dose is missed the virus is free to spread again, and taking a double dose the next day does nothing. Cabirtrovir, on the other hand, is administered by injection in the doctor's office as part of an AIDs patient's medical routine. According to clinicalinfo.hiv.gov, Cabotegravir is in Phase 3 development for HIV treatment and HIV prevention and could be available in the US as early as 2022.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.